Non-viral Reprogramming of Intervertebral Disc Cells for the treatment of Discogenic back pain
椎间盘细胞非病毒重编程治疗椎间盘源性背痛
基本信息
- 批准号:9911144
- 负责人:
- 金额:$ 36.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-20 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdolescenceAdultAnimal ModelAutomobile DrivingBehaviorBiologicalBiomedical EngineeringBlood VesselsBrachyury proteinCanis familiarisCatabolismCell Culture TechniquesCellsCellularityChronicChronic low back painClinicalClinical TrialsCognitionCommunitiesControl GroupsDNADataDevelopmentDiseaseDog DiseasesDrug AddictionEconomic BurdenEndothelial CellsEngineeringExtracellular MatrixFOXF1 geneFailureFibroblastsFibrosisFunctional disorderGAG GeneGene ProteinsGenerationsGeneticGenomeGlycosaminoglycansGoalsHealthHeightHumanHyperalgesiaIn SituIn VitroInflammationInflammatoryInjuryIntervertebral disc structureLeadLow Back PainMagnetic Resonance ImagingMechanicsMedicalMethodsModelingMusNerveOperative Surgical ProceduresOpioidPainPathologicPathologyPatientsPhasePhase TransitionPhenotypePublic HealthPuncture procedureQuality of lifeResearchResearch PersonnelResearch PriorityRodent ModelSocietiesSomatic CellSpeedStem cellsStructureSystemTechnologyTherapeuticTherapeutic EffectTissuesTransfectionTranslatingTranslational ResearchTreatment EfficacyUnited States National Institutes of HealthValidationVertebral columnVeterinariansViral VectorWorkaddictionclinically relevantcytotoxicitydiscogenic painextracellularextracellular vesiclesgene therapyhealinghuman diseaseimprovedin vivoin vivo Modelinflammatory paininnovationinterdisciplinary approachintervertebral disk degenerationminimally invasivemouse modelmultidisciplinarynanoneurotrophic factornovelnucleus pulposusopioid epidemicoptimal treatmentspain behaviorpain modelpain patientpain reliefpain symptompre-clinicalprogramsprotein expressionreduce symptomsrestorationsocioeconomicsspontaneous painstemstem cell therapytooltranscription factortranslational approachtranslational model
项目摘要
Project Summary/Abstract
Chronic low back pain exerts a significant socio-economic burden on society and is a major contributor to the
growing opioid crisis. Last year, NIH “launched the HEAL (Helping to End Addiction Long-term) initiative, an
aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis”.
This enormous burden is largely because studies have failed to target the underlying mechanisms associated
with pain generation. Intervertebral disc (IVD) degeneration is strongly associated with the pathophysiology of
low back pain and identifying non-addictive minimally invasive treatments for discogenic back pain (DBP) is a
research priority. Pathological IVD changes include extracellular matrix (ECM) breakdown, inflammation and
aberrant nerve/vascular ingrowth which have been shown to significantly correlate with pain. Therefore the
optimal therapy for DBP would target both structural restoration and reduce the symptoms of pain. Yet current
strategies involving the use of stem cells or gene therapy are faced with a number of challenges which include
failure of stem cells to adapt to the harsh IVD microenvironment, the use of viral vectors and unwarranted DNA
deletions within the host genome. Furthermore clinicians do not have access to clinically relevant tools or
technologies that could directly help treat the underlying disease in patients with DBP. There is a critical need
for a biological non-addictive strategy that addresses these limitations. Our goal is to use novel cellular
reprogramming technologies to alter the innate cell phenotype of native diseased IVD cells to a healthy
extracellular producing and anti-catabolic/inflammatory phenotype in human in vitro cell culture and in vivo
models of DBP. Non-viral delivery for transporting genetic cargo into the cell such as engineered extracellular
vesicles (EVs) or tissue nano-transfection (TNT) offer safe and minimally invasive methods for reprogramming
somatic cells and recent work by the investigators has demonstrated successful reprogramming of adult
fibroblasts into endothelial cells in vivo mouse models. We propose using these innovative non-viral delivery
systems to deliver genetic cargo to IVDs in vitro and in vivo. The first specific aim (R61 Phase 1 Aim 1) focuses
on the effects of EV or TNT delivery of transcription factors on diseased human nucleus pulposus cells and
tissue in vitro examining changes in ECM and catabolic, inflammatory and pain markers. The second aim (R61
Phase 1 Aim 2) investigates the effects of EV or TNT delivery of transcription factors in mouse IVD puncture
models of DBP assessing changes in disc structure/function, pain, cognition and cytotoxicity. These studies
are both significant and highly innovative because they combine a unique multi-disciplinary team of medical
and veterinary clinicians, spine biologists, neuroscientists, biomedical engineers, and a biostatistician to
interrogate the use of these novel concepts and technologies to treat DBP. The broader impacts of this
proposal and transition to the R33 portion involve assessing this strategy in clinically relevant
chondrodystrophic dogs that develop DBP spontaneously followed by clinical trials in patient dogs with DBP.
项目摘要/摘要
慢性下腰痛给社会带来了巨大的社会经济负担,是导致
日益严重的阿片类药物危机。去年,美国国立卫生研究院发起了Hear(帮助结束长期上瘾)倡议,
积极、跨机构的努力,以加快科学解决方案,以遏制国家阿片类药物公共卫生危机“。
这种巨大的负担在很大程度上是因为研究未能针对相关的潜在机制
伴随着痛苦的产生。椎间盘退变与腰椎间盘突出症的病理生理密切相关。
下腰痛和识别非成瘾性微创疗法治疗间盘源性腰痛(DBP)是一种
研究优先。病理性IVD改变包括细胞外基质(ECM)破坏、炎症和
异常的神经/血管内生,已被证明与疼痛显著相关。因此,
DBP的最佳治疗将以结构恢复和减轻疼痛症状为目标。目前还很流行
涉及使用干细胞或基因疗法的战略面临一些挑战,包括
干细胞无法适应恶劣的IVD微环境、使用病毒载体和不必要的DNA
宿主基因组中的缺失。此外,临床医生无法获得临床相关工具或
可以直接帮助治疗DBP患者潜在疾病的技术。有一种迫切的需要
寻求一种生物上的非成瘾策略来解决这些限制。我们的目标是使用新的蜂窝
重新编程技术将自然疾病IVD细胞的固有细胞表型改变为健康的
人体外细胞培养和体内细胞外产生及抗分解/炎症表型
DBP的模型。非病毒递送,用于将基因货物运送到细胞内,如工程细胞外
囊泡(EVS)或组织纳米转基因(TNT)为重编程提供了安全和微创的方法
体细胞和研究人员最近的工作表明,成体细胞成功地重新编程
成纤维细胞转化为内皮细胞的体内小鼠模型。我们建议使用这些创新的非病毒传递
将基因货物运送到体外和体内IVD的系统。第一个具体目标(R61阶段1目标1)重点
EV或TNT转导转录因子对人髓核病变细胞的影响
组织体外检测细胞外基质及分解代谢、炎症和疼痛标志物的变化。第二个目标(R61
阶段1目的2)研究EV或TNT转导转录因子在小鼠IVD穿刺术中的作用
评估椎间盘结构/功能、疼痛、认知和细胞毒性变化的DBP模型。这些研究
都是重要的和高度创新的,因为他们结合了一个独特的多学科医疗团队
以及兽医临床医生、脊柱生物学家、神经科学家、生物医学工程师和一名生物统计学家
询问如何使用这些新的概念和技术来治疗DBP。它的更广泛的影响
建议和过渡到R33部分涉及评估该策略在临床上的相关性
自发发生DBP的软骨营养不良犬,随后在DBP患者犬身上进行临床试验。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Non-viral Gene Delivery Methods for Bone and Joints.
- DOI:10.3389/fbioe.2020.598466
- 发表时间:2020
- 期刊:
- 影响因子:5.7
- 作者:Gantenbein B;Tang S;Guerrero J;Higuita-Castro N;Salazar-Puerta AI;Croft AS;Gazdhar A;Purmessur D
- 通讯作者:Purmessur D
Non-viral reprogramming of human nucleus pulposus cells with FOXF1 via extracellular vesicle delivery: an in vitro and in vivo study.
- DOI:10.22203/ecm.v041a07
- 发表时间:2021-01-19
- 期刊:
- 影响因子:3.1
- 作者:Tang S;Salazar-Puerta A;Richards J;Khan S;Hoyland JA;Gallego-Perez D;Walter B;Higuita-Castro N;Purmessur D
- 通讯作者:Purmessur D
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Natalia Higuita-Castro其他文献
Natalia Higuita-Castro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Natalia Higuita-Castro', 18)}}的其他基金
Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles
通过工程细胞外囊泡治疗椎间盘源性背痛的新型非病毒重编程策略
- 批准号:
10446202 - 财政年份:2022
- 资助金额:
$ 36.77万 - 项目类别:
Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles
通过工程细胞外囊泡治疗椎间盘源性背痛的新型非病毒重编程策略
- 批准号:
10606527 - 财政年份:2022
- 资助金额:
$ 36.77万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 36.77万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 36.77万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 36.77万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 36.77万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 36.77万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 36.77万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 36.77万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 36.77万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 36.77万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 36.77万 - 项目类别:
Research Grant